News ArticleFractal Analytics Surpasses $100 Million Revenue in Q2 FY27 with 139% Jump in Net Income
Consolidated operating revenue grows 20% YoY to Rs 956.5 crore led by Healthcare and BFSI sectors; EBITDA margin expands to 16%
Fractal Analytics Limited achieved its first-ever quarterly revenue crossing $100 million in Q2 FY27 with consolidated operating revenue of Rs 956.5 crore, reflecting 20% year-on-year growth. The company also reported a 139% increase in net income to Rs 79.2 crore and expanded adjusted EBITDA margin by 123 basis points to 16%. Strong growth was driven particularly by its Healthcare and Life Sciences vertical, which grew 79%, and Banking, Financial Services and Insurance sector at 30% year-on-year.
Fractal Analytics Limited
General / Other
Fractal Analytics Limited reported a record quarterly consolidated operating revenue of Rs 956.5 crore for Q2 FY27, marking its first $100 million revenue quarter with a 20% year-on-year increase. The company’s net income rose sharply by 139% to Rs 79.2 crore, alongside an expansion in adjusted EBITDA margin to 16%.
Growth was driven by significant performance in the Healthcare and Life Sciences (HLS) vertical, which recorded 79% year-on-year growth, and the Banking, Financial Services and Insurance (BFSI) sector, which grew 30%. The Consumer Packaged Goods and Retail (CPGR) vertical grew 11% year-on-year, while the Technology, Media and Telecommunications (TMT) sector showed sequential growth of 6% quarter-on-quarter.
Fractal's AI products, especially the Cogentiq agentic AI platform, reached an annual revenue run-rate exceeding Rs 150 crore, increasing 39% year-on-year. The company’s net revenue retention was 115%, reflecting increased spending from existing clients, and it maintained a Net Promoter Score of 76 during the quarter.
Profitability improved across all levels, with adjusted EBITDA margin expanding by 123 basis points to 16%, and net income more than doubling compared to the prior year period.
Fractal Analytics focuses on embedding AI into enterprise decisions with significant investment in AI R&D and continued growth across key industry verticals.
Highlights
- First quarter with consolidated operating revenue exceeding $100 million (Rs 956.5 crore)
- Consolidated revenue growth of 20% year-on-year in Q2 FY27
- Net income surged 139% year-on-year to Rs 79.2 crore
- Adjusted EBITDA margin improved to 16%, up 123 basis points year-on-year
- Healthcare and Life Sciences vertical grew 79% year-on-year
- Banking, Financial Services and Insurance vertical grew 30% year-on-year in Q2 FY27
Key Data Snapshot
What happened
- Fractal Analytics achieved its highest ever quarter with consolidated operating revenue of Rs 956.5 crore in Q2 FY27, surpassing $100 million.
- Net income more than doubled to Rs 79.2 crore compared to the same period last year.
- Adjusted EBITDA margin grew to 16%, an increase of 123 basis points year-on-year.
Key details
- Healthcare and Life Sciences vertical led revenue growth with 79% year-on-year increase.
- Banking, Financial Services and Insurance vertical grew 30% year-on-year in Q2.
- Consumer Packaged Goods and Retail grew 11% year-on-year.
- Technology, Media and Telecommunications sector recovered sequentially with 6% quarter-on-quarter growth.
- Cogentiq agentic AI platform revenue run-rate reached Rs 150 crore, up 39% year-on-year.
- The company reported a net revenue retention rate of 115% and a Net Promoter Score of 76 during the quarter.
Strategic context
- Fractal Analytics invests over 6% of revenue in AI research and development and builds proprietary AI models and platforms.
- The company targets embedding AI solutions into decision workflows of Fortune 500 enterprises across multiple industries.
- Fractal employs its flagship Cogentiq platform to power its AI services and products.
Regulatory and governance context
- The results were announced following the Board’s meeting concluded November 3, 2026.
- The financials are unaudited yet reported as consolidated results for Q2 FY27 ending September 30, 2026.
Highlights
- First quarter with consolidated operating revenue exceeding $100 million (Rs 956.5 crore)
- Consolidated revenue growth of 20% year-on-year in Q2 FY27
- Net income surged 139% year-on-year to Rs 79.2 crore
- Adjusted EBITDA margin improved to 16%, up 123 basis points year-on-year
- Healthcare and Life Sciences vertical grew 79% year-on-year
- Banking, Financial Services and Insurance vertical grew 30% year-on-year in Q2 FY27
Disclosures
- BSE Listing Requirements
- SEBI Listing Obligations and Disclosure Requirements
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
